Can-Fite BioPharma Ltd.
CANF
$1.60
▼
-0.07
(-4.19%)
at close
9
Visible periods
5
Metrics
Peer-ranked
Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome
Analytical Summary
Can-Fite BioPharma Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
Market Cap
—
Dividend Yield
—
Revenue Growth
—
Op. Margin
—
ROIC
—
FCF / Share
—
Trailing P/E
—
Price / Book
0.8x
FCF Yield
—
Debt / Equity
—
info
Valuation on last close. End-of-day price, Nov 5, 2026.
trending_up
Bullish Indicators
- No bullish signals detected.
warning
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Returns ↓
3
Cash Quality ↑
61
Financial view
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
Is the balance sheet risky?
1 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ | Q4 FY2017 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Net Debt (USD) | $-5.53M | $-4.83M | $-4.28M | $-2.98M | $-4.39M | $-8.27M | $-2.70M | $-3.62M | $-3.50M |
How resilient is the balance sheet?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ | Q4 FY2017 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $6.71M | $6.93M | $7.89M | $6.66M | $17.34M | $8.13M | $3.87M | — | — |
| Total Equity (USD) | $5.59M | $5.44M | $6.24M | $4.47M | $14.38M | $6.07M | $2.44M | $3.02M | $2.98M |
⌨️ Keyboard Shortcuts
/ Search
Esc Clear
A Annual
Q Quarterly
1-7 Jump to category
R Reset
Secondary lens
Benchmark Lens
Compare CANF against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare CANF against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for CANF
Bullish
0
No bullish signals detected
Bearish
1
Return on Common Equity (%)
-175.8%
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How CANF compares to all companies
Return on Common Equity (%)
-175.8%
Bottom 25%
Peers: Top 95%
Peer Comparison
CANF vs similar peers
Return on Common Equity (%)
CANF
-175.8%
#111 of 117
QTTB
71.0%
ABEO
44.7%
XOMA
37.8%
Peer median: -49.09
Profit Margin (%)
CANF
—
#None of 26
XOMA
60.8%
QTTB
55.5%
SIGA
24.6%
Peer median: -21.61
Debt to Equity
CANF
—
#None of 34
BIOA
0.00x
ABUS
0.00x
RANI
0.00x
Peer median: 0.19
Operating Margin (%)
CANF
—
#None of 25
QTTB
31.5%
SIGA
25.1%
ELTP
23.3%
Peer median: -29.35
Compare CANF with peers
Stack CANF against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 4 days ago 10 years · 9 quarters